S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:LIFE

aTyr Pharma (LIFE) Stock Price, News & Analysis

$1.95
-0.05 (-2.50%)
(As of 03/28/2024 ET)
Today's Range
$1.89
$2.05
50-Day Range
$1.50
$2.02
52-Week Range
$1.08
$2.70
Volume
726,105 shs
Average Volume
682,650 shs
Market Capitalization
$132.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.67

aTyr Pharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
1,113.7% Upside
$23.67 Price Target
Short Interest
Healthy
0.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of aTyr Pharma in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.97) to ($1.03) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.25 out of 5 stars

Medical Sector

630th out of 939 stocks

Biological Products, Except Diagnostic Industry

103rd out of 155 stocks

LIFE stock logo

About aTyr Pharma Stock (NASDAQ:LIFE)

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

LIFE Stock Price History

LIFE Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Recap: aTyr Pharma Q4 Earnings
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Q4 2023 aTyr Pharma Inc Earnings Call
Atyr Pharma: Q4 Earnings Snapshot
aTyr Pharma's Earnings Outlook
The 3 Best Penny Stocks to Buy in February 2024
See More Headlines
Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2021
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:LIFE
CUSIP
53217V10
Employees
65
Year Founded
2005

Price Target and Rating

Average Stock Price Target
$23.67
High Stock Price Target
$35.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+1,113.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-50,390,000.00
Pretax Margin
-14,276.77%

Debt

Sales & Book Value

Annual Sales
$350,000.00
Book Value
$1.54 per share

Miscellaneous

Free Float
65,623,000
Market Cap
$132.11 million
Optionable
Optionable
Beta
1.25

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Sanjay S. Shukla M.D. (Age 52)
    M.S., President, CEO & Director
    Comp: $795.48k
  • Ms. Jill M. BroadfootMs. Jill M. Broadfoot (Age 62)
    Chief Financial Officer
    Comp: $556.62k
  • Ms. Nancy E. Denyes Krueger (Age 56)
    General Counsel & Corporate Secretary
    Comp: $532.13k
  • Xiang-Lei Yang Ph.D.
    Founder
  • Ms. Ashlee Dunston
    Director of Investor Relations & Corporate Communications
  • Mr. Peter Villiger
    Vice President of Corporate Development
  • Ms. Danielle Campbell
    VP of Human Resource
  • Dr. Leslie Nangle Ph.D.
    Vice President of Research
  • Dr. Ying J. Buechler Ph.D.
    Executive Director of Biologics Development & Manufacturing
  • Dr. David J. King Ph.D. (Age 65)
    Scientific Consultant
    Comp: $327.31k

LIFE Stock Analysis - Frequently Asked Questions

Should I buy or sell aTyr Pharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LIFE shares.
View LIFE analyst ratings
or view top-rated stocks.

What is aTyr Pharma's stock price target for 2024?

4 Wall Street research analysts have issued 12-month target prices for aTyr Pharma's shares. Their LIFE share price targets range from $16.00 to $35.00. On average, they predict the company's share price to reach $23.67 in the next twelve months. This suggests a possible upside of 1,113.7% from the stock's current price.
View analysts price targets for LIFE
or view top-rated stocks among Wall Street analysts.

How have LIFE shares performed in 2024?

aTyr Pharma's stock was trading at $1.41 on January 1st, 2024. Since then, LIFE shares have increased by 38.3% and is now trading at $1.95.
View the best growth stocks for 2024 here
.

Are investors shorting aTyr Pharma?

aTyr Pharma saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 289,300 shares, an increase of 167.4% from the February 29th total of 108,200 shares. Based on an average daily trading volume, of 521,200 shares, the short-interest ratio is currently 0.6 days.
View aTyr Pharma's Short Interest
.

When is aTyr Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our LIFE earnings forecast
.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) released its earnings results on Monday, August, 9th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.13.

When did aTyr Pharma's stock split?

Shares of aTyr Pharma reverse split before market open on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

When did aTyr Pharma IPO?

aTyr Pharma (LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.04%), Vanguard Group Inc. (4.04%), Stonepine Capital Management LLC (0.82%), Pale Fire Capital SE (0.50%), Goldman Sachs Group Inc. (0.25%) and Goldman Sachs Group Inc. (0.25%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends
.

How do I buy shares of aTyr Pharma?

Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIFE) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners